Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Apr 17 04:00PM ET
66.47
Dollar change
-1.48
Percentage change
-2.18
%
IndexRUT P/E- EPS (ttm)-0.91 Insider Own8.18% Shs Outstand109.36M Perf Week-7.23%
Market Cap7.27B Forward P/E- EPS next Y-1.52 Insider Trans-5.33% Shs Float100.41M Perf Month4.93%
Income-85.89M PEG- EPS next Q-0.28 Inst Own69.82% Short Float9.48% Perf Quarter210.32%
Sales0.00M P/S- EPS this Y-23.49% Inst Trans-0.29% Short Ratio1.48 Perf Half Y517.75%
Book/sh3.48 P/B19.10 EPS next Y-34.95% ROA-31.99% Short Interest9.52M Perf Year238.61%
Cash/sh3.31 P/C20.08 EPS next 5Y40.00% ROE-34.79% 52W Range8.28 - 99.41 Perf YTD257.17%
Dividend Est.- P/FCF- EPS past 5Y-18.89% ROI-24.59% 52W High-33.14% Beta1.16
Dividend TTM- Quick Ratio19.19 Sales past 5Y0.00% Gross Margin- 52W Low702.78% ATR (14)5.34
Dividend Ex-Date- Current Ratio19.19 EPS Y/Y TTM-2.06% Oper. Margin0.00% RSI (14)45.72 Volatility4.20% 6.77%
Employees27 Debt/Eq0.00 Sales Y/Y TTM- Profit Margin- Recom1.09 Target Price112.26
Option/ShortYes / Yes LT Debt/Eq0.00 EPS Q/Q3.76% Payout- Rel Volume0.31 Prev Close67.95
Sales Surprise- EPS Surprise1.57% Sales Q/Q- EarningsApr 24 AMC Avg Volume6.45M Price66.47
SMA20-9.68% SMA507.15% SMA200149.16% Trades Volume1,967,900 Change-2.18%
Date Action Analyst Rating Change Price Target Change
Mar-26-24Reiterated Oppenheimer Outperform $116 → $138
Mar-07-24Initiated Jefferies Buy $110
Feb-28-24Reiterated Oppenheimer Outperform $46 → $116
May-31-23Resumed ROTH MKM Buy $32
Mar-28-23Reiterated Maxim Group Buy $15 → $25
Mar-17-23Initiated Stifel Buy $22
Jul-29-21Resumed BTIG Research Buy $20
May-25-21Downgrade Raymond James Strong Buy → Outperform $27 → $12
Jun-05-20Initiated BMO Capital Markets Outperform $14
May-05-20Initiated Chardan Capital Markets Buy $15
Apr-17-24 04:05PM
Apr-13-24 08:47AM
Apr-11-24 01:49PM
12:24PM
Apr-10-24 05:45PM
08:59AM Loading…
08:59AM
Apr-09-24 10:00AM
06:45AM
Apr-08-24 05:55AM
Apr-06-24 08:47PM
07:45AM
Apr-05-24 07:15AM
Apr-04-24 09:15AM
06:30AM
05:50AM
04:55AM Loading…
04:55AM
Apr-02-24 05:50AM
Apr-01-24 01:49PM
Mar-31-24 10:15PM
09:31AM
06:15AM
Mar-29-24 09:15AM
09:00AM
08:51AM
Mar-28-24 01:50PM
10:52AM
05:50AM
Mar-27-24 12:42PM
12:22PM
Mar-26-24 04:15PM
01:25PM Loading…
01:25PM
01:02PM
12:59PM
11:58AM
11:28AM
11:17AM
11:15AM
11:13AM
10:57AM
10:07AM
08:06AM
07:12AM
07:09AM
07:03AM
05:51AM
04:11AM
Mar-25-24 06:25AM
Mar-24-24 09:15AM
Mar-23-24 05:53AM
Mar-22-24 04:55AM
Mar-21-24 08:49AM
Mar-20-24 08:30AM
08:00AM
Mar-19-24 09:45AM
Mar-17-24 09:15AM
08:50AM
Mar-16-24 08:17AM
Mar-15-24 09:45AM
05:50AM
Mar-14-24 09:38AM
Mar-13-24 07:35AM
05:03AM
Mar-11-24 06:53AM
Mar-09-24 04:47PM
Mar-08-24 01:03PM
06:47AM
Mar-07-24 12:05PM
Mar-06-24 05:50AM
Mar-05-24 11:16AM
06:15AM
Mar-04-24 04:45PM
05:58AM
Mar-03-24 09:35AM
07:41AM
Mar-01-24 05:59PM
12:11PM
07:31AM
Feb-29-24 02:21PM
09:00AM
07:45AM
06:42AM
06:00AM
04:53AM
Feb-28-24 08:50PM
04:56PM
12:23PM
11:23AM
11:01AM
10:00AM
07:30AM
Feb-27-24 10:15PM
06:01PM
05:35PM
04:22PM
04:19PM
04:06PM
03:50PM
11:21AM
09:47AM
09:39AM
Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Lian BrianPresident & CEOFeb 09 '24Sale29.9045,0001,345,5002,139,882Feb 09 08:59 PM
Lian BrianPresident & CEOFeb 08 '24Option Exercise3.76189,079711,3672,404,882Feb 08 07:40 PM
Rouan Sarah KathrynDirectorFeb 08 '24Option Exercise8.3225,000208,00025,000Feb 08 07:38 PM
Lian BrianPresident & CEOFeb 08 '24Sale26.87269,0797,230,7842,184,882Feb 08 07:40 PM
Rouan Sarah KathrynDirectorFeb 08 '24Sale28.0525,000701,2500Feb 08 07:38 PM
Lian BrianPresident & CEOJan 31 '24Option Exercise1.2385,000104,5502,349,882Jan 31 08:39 PM
Lian BrianPresident & CEOJan 31 '24Sale24.7185,0002,100,7502,264,882Jan 31 08:39 PM
Lian BrianPresident & CEOJan 30 '24Option Exercise1.2335,00043,0502,299,882Jan 30 09:05 PM
Lian BrianPresident & CEOJan 30 '24Sale23.9535,000838,2502,264,882Jan 30 09:05 PM
Rouan Sarah KathrynDirectorJan 19 '24Option Exercise8.3230,000249,60030,000Jan 19 08:35 PM
Rouan Sarah KathrynDirectorJan 19 '24Sale23.0530,000691,5000Jan 19 08:35 PM
ZANTE GREGChief Financial OfficerJan 04 '24Sale17.9015,000268,500180,730Jan 04 09:35 PM
Rowland Charles A JrDirectorMay 16 '23Option Exercise1.0840,00043,20070,000May 18 06:31 PM
MACARTNEY LAWSONDirectorMay 16 '23Option Exercise1.1916,00019,04063,965May 18 06:30 PM
Rowland Charles A JrDirectorMay 16 '23Sale25.0040,0001,000,00030,000May 18 06:31 PM
MACARTNEY LAWSONDirectorMay 16 '23Sale24.0016,000384,00047,965May 18 06:30 PM
Lian BrianPresident & CEOMay 01 '23Sale22.4545,0001,010,2502,197,963May 01 07:03 PM
MACARTNEY LAWSONDirectorApr 24 '23Option Exercise3.3316,00053,28063,965Apr 24 07:31 PM
MACARTNEY LAWSONDirectorApr 24 '23Sale22.0016,000352,06147,965Apr 24 07:31 PM
Lian BrianPresident & CEOApr 19 '23Sale21.4535,000750,7502,242,963Apr 21 07:29 PM